Bevacizumab specifically binds to human VEGF and blocks its biological activity by inhibiting its binding to VEGF receptors on vascular endothelial cells, thereby preventing tumor growth by inhibiting angiogenesis in tumor tissues [3,4]. The gene discussed is VEGFA; the disease is neoplasm.